Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 609, doi. 10.1007/s13300-014-0074-y
- By:
- Publication type:
- Article
Works matching IS 18696953 AND DT 2014 AND VI 5 AND IP 2
Results: 20
1
2
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 447, doi. 10.1007/s13300-014-0075-x
- By:
- Publication type:
- Article
3
Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 435, doi. 10.1007/s13300-014-0076-9
- By:
- Publication type:
- Article
4
Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 347, doi. 10.1007/s13300-014-0077-8
- By:
- Publication type:
- Article
5
A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 403, doi. 10.1007/s13300-014-0078-7
- By:
- Publication type:
- Article
6
Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 567, doi. 10.1007/s13300-014-0079-6
- By:
- Publication type:
- Article
7
Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 591, doi. 10.1007/s13300-014-0080-0
- By:
- Publication type:
- Article
8
Initial Experience and Evaluation of Reusable Insulin Pen Devices Among Patients with Diabetes in Emerging Countries.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 545, doi. 10.1007/s13300-014-0081-z
- By:
- Publication type:
- Article
9
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 459, doi. 10.1007/s13300-014-0082-y
- By:
- Publication type:
- Article
10
Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 483, doi. 10.1007/s13300-014-0083-x
- By:
- Publication type:
- Article
11
Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 579, doi. 10.1007/s13300-014-0084-9
- By:
- Publication type:
- Article
12
Role of Comorbidities as Limiting Factors to the Effect of Hyperbaric Oxygen in Diabetic Foot Patients: A Retrospective Analysis.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 535, doi. 10.1007/s13300-014-0085-8
- By:
- Publication type:
- Article
13
Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 415, doi. 10.1007/s13300-014-0086-7
- By:
- Publication type:
- Article
14
Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 499, doi. 10.1007/s13300-014-0087-6
- By:
- Publication type:
- Article
15
A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 521, doi. 10.1007/s13300-014-0088-5
- By:
- Publication type:
- Article
16
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 355, doi. 10.1007/s13300-014-0089-4
- By:
- Publication type:
- Article
17
Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 471, doi. 10.1007/s13300-014-0090-y
- By:
- Publication type:
- Article
18
A Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 385, doi. 10.1007/s13300-014-0091-x
- By:
- Publication type:
- Article
19
Improving Self-Monitoring of Blood Glucose among Adults with Type 1 Diabetes: Results of the Mobile™ Study.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 557, doi. 10.1007/s13300-014-0092-9
- By:
- Publication type:
- Article
20
The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 367, doi. 10.1007/s13300-014-0073-z
- By:
- Publication type:
- Article